

# APPENDIX Z

---

SEPTEMBER 7, 1990

MEMORANDUM OF MEETING BETWEEN THE DEPARTMENT OF  
DEFENSE AND THE FOOD AND DRUG ADMINISTRATION

MEMORANDUM

DATE : September 7, 1990  
 FROM : Richard Klein and Ann Graham  
 SUBJ : September 7th meeting between FDA and DoD  
 TO : Stuart Nightingale

The following were in attendance at the meeting:

Department of Defense

Craig Lehmann	U.S. Army Medical R & D Command
Ronald Clawson	U.S. Army Medical R & D Command
Gregory Berezuk	U.S Army Human Use and Regulatory Affairs
George Sisson	Command Judge Advocate, Army Medical R & D
Walt Brandt	Army Biologics

FDA

Stuart Nightingale  
 Margaret Porter  
 Catherine Lorraine  
 William Lampkin  
 Carl Peck  
 Jim Bilstad  
 Ann Sutton  
 Karen Goldenthal  
 Robert Temple  
 Paula Botstein  
 Bill Damaska  
 Robert Sheridan  
 Ann Graham  
 Richard Klein  
 Linda Carter  
 Bonnie Lee  
 Ron Wilson  
 Ann Witt

- o DoD will submit to FDA for review the training doctrine currently being developed for each product
- o DoD will submit updated information on each product on an ad hoc basis, but at least once a week.
- o FDA and DoD agreed to find a common interpretation of 10 USC 980 and 21 CFR 312 allowing DoD to comply with their statute and FDA regulations simultaneously.

- o OHA will track the status of all DoD products being used for unique military purposes.
- o DoD agreed to revise their protocols to expand post exposure observations in battlefield observations.
- o Margaret Porter agreed to review and revise draft informed consent regulation, and bring it to the direct attention of the Commissioner.
- o DoD still insists on a safety review under the terms of the MOU.
- o Under the DoD directive the Secretary of Military Departments can dictate the use of unapproved FDA regulated products. DoD's current position is that this is not their primary choice at this time.
- \* o DoD indicated that they want FDA review and agency assurance that the drugs are safe, as well as that their use is appropriate.
- o OHA agreed to play a clearinghouse role for FDA, tracking drugs and medical devices.
- o OHA and OGC will follow-up with George Sisson concerning the status of skin creme product.